Conduent stock hits 52-week low at $2.84 amid market challenges

Published 28/03/2025, 14:52
Conduent stock hits 52-week low at $2.84 amid market challenges

Conduent Incorporated (NASDAQ:CNDT), a provider of diversified business services, has seen its stock price touch a 52-week low, reaching $2.84. With a market capitalization of $461 million and a P/E ratio of 1.27, InvestingPro analysis suggests the stock is currently trading below its Fair Value. This latest price movement reflects a challenging period for the company, which has experienced a significant downturn over the past year. The stock’s performance, marked by this new low, underscores a broader trend for Conduent, with a year-to-date decline of nearly 29% and concerning cash burn rates. InvestingPro data reveals the stock is trading at just 0.55 times book value, suggesting potential value opportunity despite operational challenges. Investors are closely monitoring the company’s strategic initiatives and market position, as Conduent navigates through the headwinds that have impacted its stock value. While the company maintains a current ratio of 1.68, indicating adequate liquidity, InvestingPro analysis highlights 12 additional key factors affecting the company’s outlook, available in the comprehensive Pro Research Report.

In other recent news, Conduent Incorporated reported its Q4 2024 earnings, which revealed a slight miss on earnings per share (EPS), coming in at -$0.15 compared to the forecasted -$0.12. The company’s revenue also fell short, totaling $800 million against an expected $806.33 million. Despite these results, Conduent has outlined a strategic focus on leveraging AI technologies and expanding offshore capabilities. The company has set a revenue guidance range of $3.100-$3.250 billion for 2025, with an adjusted EBITDA margin expected between 4.5% and 5.5%. In other developments, Ireland’s Health Service Executive (HSE) has entered into a five-year contract with Conduent to implement the Maven® Disease Surveillance & Outbreak Management System, marking its first deployment in the European Union. This system aims to enhance disease tracking and management capabilities by automating the generation of disease events from case or laboratory reports. Maven is already utilized by 28 government agencies worldwide, showcasing its global reach. Additionally, Conduent continues to focus on strategic initiatives such as AI implementation and offshore expansion to drive future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.